255 related articles for article (PubMed ID: 37563605)
1. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.
Pavlakis E; Neumann M; Merle N; Wieboldt R; Wanzel M; Ponath V; Pogge von Strandmann E; Elmshäuser S; Stiewe T
J Exp Clin Cancer Res; 2023 Aug; 42(1):203. PubMed ID: 37563605
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5.
Vogiatzi F; Brandt DT; Schneikert J; Fuchs J; Grikscheit K; Wanzel M; Pavlakis E; Charles JP; Timofeev O; Nist A; Mernberger M; Kantelhardt EJ; Siebolts U; Bartel F; Jacob R; Rath A; Moll R; Grosse R; Stiewe T
Proc Natl Acad Sci U S A; 2016 Dec; 113(52):E8433-E8442. PubMed ID: 27956623
[TBL] [Abstract][Full Text] [Related]
3. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.
Li D; Marchenko ND; Moll UM
Cell Death Differ; 2011 Dec; 18(12):1904-13. PubMed ID: 21637290
[TBL] [Abstract][Full Text] [Related]
4. Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1.
Tong X; Xu D; Mishra RK; Jones RD; Sun L; Schiltz GE; Liao J; Yang GY
J Biol Chem; 2021; 296():100098. PubMed ID: 33208462
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic Cancer Progression Relies upon Mutant p53-Induced Oncogenic Signaling Mediated by NOP14.
Du Y; Liu Z; You L; Hou P; Ren X; Jiao T; Zhao W; Li Z; Shu H; Liu C; Zhao Y
Cancer Res; 2017 May; 77(10):2661-2673. PubMed ID: 28280038
[TBL] [Abstract][Full Text] [Related]
6. The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells.
Klemke L; Fehlau CF; Winkler N; Toboll F; Singh SK; Moll UM; Schulz-Heddergott R
Front Oncol; 2021; 11():642603. PubMed ID: 34178628
[TBL] [Abstract][Full Text] [Related]
7. Proteasomal and autophagy-mediated degradation of mutp53 proteins through mitochondria-targeting aggregation-induced-emission materials.
Wang M; Yang Z; Song Y; Wei P; Ishiwme N; Wang L; Zhang H; Jing M; Gao M; Wen L; Zhang Y
Acta Biomater; 2022 Sep; 150():402-412. PubMed ID: 35931280
[TBL] [Abstract][Full Text] [Related]
8. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.
Alexandrova EM; Yallowitz AR; Li D; Xu S; Schulz R; Proia DA; Lozano G; Dobbelstein M; Moll UM
Nature; 2015 Jul; 523(7560):352-6. PubMed ID: 26009011
[TBL] [Abstract][Full Text] [Related]
9. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells.
Cai J; Xia J; Zou J; Wang Q; Ma Q; Sun R; Liao H; Xu L; Wang D; Guo X
FEBS Open Bio; 2020 Apr; 10(4):535-545. PubMed ID: 32027103
[TBL] [Abstract][Full Text] [Related]
10. In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis.
Li Y; Xiao Y; Lin HP; Reichel D; Bae Y; Lee EY; Jiang Y; Huang X; Yang C; Wang Z
Biomaterials; 2019 Jan; 188():160-172. PubMed ID: 30352320
[TBL] [Abstract][Full Text] [Related]
11. Association of the thyrotropin receptor with calnexin, calreticulin and BiP. Efects on the maturation of the receptor.
Siffroi-Fernandez S; Giraud A; Lanet J; Franc JL
Eur J Biochem; 2002 Oct; 269(20):4930-7. PubMed ID: 12383251
[TBL] [Abstract][Full Text] [Related]
12. Calnexin, calreticulin, and ERp57 cooperate in disulfide bond formation in human CD1d heavy chain.
Kang SJ; Cresswell P
J Biol Chem; 2002 Nov; 277(47):44838-44. PubMed ID: 12239218
[TBL] [Abstract][Full Text] [Related]
13. Pro-metastatic p53 mutants control folding of N-glycoproteins.
Schneikert J; Stiewe T
Cell Cycle; 2017 Apr; 16(7):591-592. PubMed ID: 28166433
[No Abstract] [Full Text] [Related]
14. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.
Wei S; Wang H; Lu C; Malmut S; Zhang J; Ren S; Yu G; Wang W; Tang DD; Yan C
J Biol Chem; 2014 Mar; 289(13):8947-59. PubMed ID: 24554706
[TBL] [Abstract][Full Text] [Related]
15. Precise pancreatic cancer therapy through targeted degradation of mutant p53 protein by cerium oxide nanoparticles.
Zhang H; Zhang W; Hu B; Qin X; Yi T; Ye Y; Huang X; Song Y; Yang Z; Qian J; Zhang Y
J Nanobiotechnology; 2023 Apr; 21(1):117. PubMed ID: 37005668
[TBL] [Abstract][Full Text] [Related]
16. BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function.
Yue X; Zhao Y; Liu J; Zhang C; Yu H; Wang J; Zheng T; Liu L; Li J; Feng Z; Hu W
Elife; 2015 Aug; 4():. PubMed ID: 26271008
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
[TBL] [Abstract][Full Text] [Related]
18. Contrasting functions of calreticulin and calnexin in glycoprotein folding and ER quality control.
Molinari M; Eriksson KK; Calanca V; Galli C; Cresswell P; Michalak M; Helenius A
Mol Cell; 2004 Jan; 13(1):125-35. PubMed ID: 14731400
[TBL] [Abstract][Full Text] [Related]
19. Steroid receptor coactivator-1 upregulates integrin α₅ expression to promote breast cancer cell adhesion and migration.
Qin L; Chen X; Wu Y; Feng Z; He T; Wang L; Liao L; Xu J
Cancer Res; 2011 Mar; 71(5):1742-51. PubMed ID: 21343398
[TBL] [Abstract][Full Text] [Related]
20. Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53.
Zhao Y; Zhang C; Yue X; Li X; Liu J; Yu H; Belyi VA; Yang Q; Feng Z; Hu W
Cell Death Differ; 2015 Nov; 22(11):1824-36. PubMed ID: 25857266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]